Literature DB >> 2125531

A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer.

J L Speyer1, M D Green, J Sanger, A Zeleniuch-Jacquotte, E Kramer, M Rey, J C Wernz, R H Blum, H Hochester, M Meyers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2125531     DOI： 10.1016/0305-7372(90)90041-d

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  5 in total

Review 1.  Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Authors:  Eric S Christenson; Theodore James; Vineet Agrawal; Ben H Park
Journal:  Clin Biochem       Date:  2014-11-07       Impact factor: 3.281

2.  Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.

Authors:  Evert L de Beer; Antonio E Bottone; Maartje C van Rijk; Jolanda van der Velden; Emile E Voest
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

Review 3.  Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.

Authors:  James H Doroshow
Journal:  Curr Pharm Biotechnol       Date:  2012-08       Impact factor: 2.837

Review 4.  Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.

Authors:  Esmée C de Baat; Renée L Mulder; Saro Armenian; Elizabeth Am Feijen; Heynric Grotenhuis; Melissa M Hudson; Annelies Mc Mavinkurve-Groothuis; Leontien Cm Kremer; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2022-09-27

Review 5.  Cardioprotective interventions for cancer patients receiving anthracyclines.

Authors:  Elvira C van Dalen; Huib N Caron; Heather O Dickinson; Leontien Cm Kremer
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.